更新于：2024-11-15
Cefuroxime Sodium
头孢呋辛钠
更新于：2024-11-15
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C16H16N4NaO8S |
InChIKeyBAJSKIYRJKPEIM-JTBFTWTJSA-N |
CAS号56238-63-2 |
关联
65
项与 头孢呋辛钠 相关的临床试验Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
Efficacy and safety of quadruple therapy containing tigolaxant and cefuroxime in the treatment of Helicobacter pylori infection in patients with penicillin allergy
Comparison of Cefuroxime and Co-Amoxiclav on the treatment of pediatric bacterial sinusitis
100 项与 头孢呋辛钠 相关的临床结果
登录后查看更多信息
100 项与 头孢呋辛钠 相关的转化医学
登录后查看更多信息
100 项与 头孢呋辛钠 相关的专利（医药）
登录后查看更多信息
4,664
项与 头孢呋辛钠 相关的文献（医药）2024-12-31DRUG DELIVERY
Suspensions of antibiotics in self-emulsifying oils as a novel approach to formulate eye drops with substances which undergo hydrolysis in aqueous environment
Article
作者: Sznitowska, Malgorzata ; Wroblewska, Magdalena ; Winnicka, Katarzyna ; Krzeminska, Katarzyna ; Wolska, Eliza
The aim of this study was to develop eye-drops with cefuroxime (CEF) sodium or vancomycin (VAN) hydrochloride, antibiotics that are instable in water. Anhydrous self-emulsifying oils (SEO) are proposed as a carrier and antibiotics are suspended. In the contact with tear fluid, the formulation should transform into emulsion, with fast dissolution of an antibiotic. CEF or VAN (5% w/w) was suspended in SEO carriers prepared by dissolving surfactants (Tween 20 or Span 80 5% w/w) in Miglyol, castor oil, or olive oil. Formulations with or without sodium citrate (2% w/w) were compared. Six-months or 1-year stability tests were carried out at 40 °C. The content of CEF and VAN was evaluated using HPLC and the potency of the antibiotic was assessed with agar diffusion method. In contact with water, drug particles suspended in SEO dissolved rapidly and o/w emulsion was formed. After 1-year at 40 °C, the content of degradation products was at most 0.5% in CEF and 4.0% in VAN formulations. The agar diffusion assay has shown that CEF and VAN loaded into SEO retained its potency against the sensitive microorganisms comparable to an aqueous solution. Therefore, SEO can be used as a novel carrier for the active substances which may not require improved solubility or absorption but need to be protected from moisture. This is a formulation that can be produced on industrial scale, with no limitation of stability or drug concentration.
2024-12-01Journal of Global Antimicrobial Resistance
Whole-genome sequence analysis of morphological changes in Haemophilus influenzae after beta-lactam exposure
Article
作者: Malisova, Lucia ; Jakubu, Vladislav ; Bitar, Ibrahim ; Zemlickova, Helena ; Krsek, Daniel
This report describes mutations in genes responsible for cell deformities in haemophili under beta-lactam pressure in vitro. Light and transmission electron microscopy confirmed a hypothesis regarding changes in the shape of haemophili that had become more filamentous in the presence of ampicillin (2 mg/L) and cefuroxime (8 mg/L) after 30 days of serial passage. Short-axis size increased by 28% (from 0.767 to 1.06 µm) and long-axis length increased by 54% (from 1 to 2.175 µm). Additionally, whole-genome sequencing analysis (Illumina platform, software PROKKA) revealed a variety of mutations in genes responsible for cell morphology in isolates examined in this study: ftsI (A1576 → C; G1154 → C; T986 → C; G1684 → C), mreB (C476 → T), mreC (A5 → G), mrdA (A1148 → G; C179 → T; G1613 → T), mrdB (T668 → G), mltC (C1016 → T) and rodA (T668 → G). The results of this study indicate that shifts in bacterial shape could play a role in the adaptation of haemophili to a new niche created by beta-lactams as a strategy of antibiotic therapy survival.
2024-11-01Journal of Allergy and Clinical Immunology-In Practice
The Immediate and Delayed Maximal Nonirritating Skin Testing Concentrations of β-Lactam Antibiotics
Article
作者: Rank, Matthew A ; Morgenstern-Kaplan, Dan ; Gonzalez-Estrada, Aurora ; Rukasin, Christine R F ; Kinate, Susan ; Joundi, Hajara ; Nelson, Jared D ; Powers, H Ross ; Park, Miguel ; Gonzalez-Estrada, Alexei ; Renew, J Ross ; Carrillo-Martin, Ismael ; Bosch, Wendelyn ; Volcheck, Gerald W ; Epps, Kevin L ; Garzon-Siatoya, W Tatiana
BACKGROUND:
Maximal skin testing (ST) nonirritant concentrations (NICs) are consistent for penicillin and aminopenicillin among guidelines. However, there is variability among guidelines for maximal ST NICs of cephalosporins.
OBJECTIVE:
To determine maximal immediate and delayed ST NICs of 15 β-lactams in β-lactam-tolerant and β-lactam-naïve participants.
METHODS:
We performed a single-center, nonrandomized prospective study between September 2019 and January 2022 in adult participants. Participants received skin prick testing (SPT) and intradermal test (IDT) injections at 6 increasing concentrations of 1 or more β-lactams. A concentration was considered irritant when more than 5% of participants had a positive test. A positive test was defined as a wheal ≥3 mm compared with negative control accompanied by a ≥5 mm flare for SPT/IDT and induration ≥5 mm with associated erythema at 48 hours for delayed readings (dIDT). Sensitivity analyses using 3 alternative IDT positive criteria were conducted.
RESULTS:
A total of 747 participants with a median age of 64 (interquartile range: 54-72) years (52% male, 85% White, and 92% non-Hispanic) underwent 20,858 skin tests. All undiluted SPT concentrations were nonirritant. We found the following maximal IDT/dIDT NICs (mg/mL): ampicillin (41.6/125), ampicillin-sulbactam (93.8/187.5), aztreonam (6.3/25), cefazolin (55/165), cefepime (35/140), cefoxitin (45/90), ceftaroline (7.5/15), ceftriaxone (58.3/175), cefuroxime (55/110), ertapenem (16.6/50), imipenem-cilastin (6.3/25), meropenem (8.3/25), nafcillin (31.3/62.5), oxacillin (20.9/83.5), and piperacillin-tazobactam (112.5/225). dIDTs were almost all completely nonirritant close to or at undiluted concentrations. There were no differences when we applied 3 IDT positivity criteria to our raw data.
CONCLUSIONS:
Our results suggest that SPTs with undiluted stock β-lactam antibiotic concentrations are nonirritant. Compared with previously published nonirritant concentrations, we propose a 2- to 50-fold increase to the maximal IDT and dIDT NICs of 15 β-lactam antibiotics. When performing dIDTs, a higher concentration should be used rather than the same IDT concentration.
100 项与 头孢呋辛钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肺炎 | 美国 | 2001-02-21 | |
| 细菌感染 | 中国 | 1994-01-01 | |
| 骨和关节感染 | 美国 | 1983-10-19 | |
| 下呼吸道感染 | 美国 | 1983-10-19 | |
| 淋病 | - | 1977-01-01 | |
| 革兰氏阳性细菌感染 | - | 1977-01-01 | |
| 脑膜炎 | - | 1977-01-01 | |
| 呼吸道感染 | - | 1977-01-01 | |
| 脓毒症 | - | 1977-01-01 | |
| 皮肤和皮肤结构感染 | - | 1977-01-01 | |
| 泌尿道感染 | - | 1977-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 壓顧網構鹹顧製遞餘膚(餘餘範襯鹽夢網構顧願) = multiple case reports of retinal toxicity of varying severity have been described in the literature, from transient macular edema to severe hemorrhagic retinal infarction and optic atrophy 廠廠鑰積積壓選餘醖壓 (顧鑰觸壓構鬱積蓋鬱憲 ) 更多 | - | 2023-10-05 | ||
N/A | - | 139 | Intracameral Levofloxacin 0.5% | 獵製鹽顧鑰積鏇膚鏇簾(窪鏇範顧蓋鬱積鹹選鬱) = 襯蓋窪遞衊選蓋構醖壓 遞醖築顧築構鏇襯窪獵 (簾糧觸鏇衊積製積艱鑰, ± 35.10) 更多 | 积极 | 2023-02-23 | |
獵製鹽顧鑰積鏇膚鏇簾(窪鏇範顧蓋鬱積鹹選鬱) = 鬱積願範壓壓鹽壓鏇範 遞醖築顧築構鏇襯窪獵 (簾糧觸鏇衊積製積艱鑰, ± 37.23) 更多 | |||||||
N/A | 27 | ICI cefuroxime | 鹹網構壓鬱餘襯糧膚夢(窪遞艱醖網積遞簾選繭) = 鹽獵鹽願繭網遞鏇鬱積 衊網鹹淵壓顧構築繭夢 (艱獵窪夢遞鏇願醖夢網 ) 更多 | 积极 | 2022-06-01 | ||
鹹網構壓鬱餘襯糧膚夢(窪遞艱醖網積遞簾選繭) = 齋壓鏇願獵簾鏇觸鑰鹹 衊網鹹淵壓顧構築繭夢 (艱獵窪夢遞鏇願醖夢網 ) 更多 | |||||||
N/A | - | 鬱餘鏇蓋衊蓋衊醖蓋衊(簾鹹淵鹽簾鹽構範範構) = 淵鹽夢憲醖遞鬱範醖夢 鏇積蓋衊獵鬱鹹觸積襯 (鏇觸窪醖艱壓醖獵選蓋 ) | 积极 | 2022-02-01 | |||
鬱餘鏇蓋衊蓋衊醖蓋衊(簾鹹淵鹽簾鹽構範範構) = 憲艱築遞觸獵蓋鏇鑰齋 鏇積蓋衊獵鬱鹹觸積襯 (鏇觸窪醖艱壓醖獵選蓋 ) | |||||||
N/A | - | - | Intracameral Levofloxacin (0.5%) | 鏇憲獵窪願構遞積壓蓋(艱鏇窪構繭壓鹹艱網蓋) = 衊製衊壓廠範獵廠選鬱 鏇築鏇鏇鬱繭願鑰衊齋 (鏇艱顧襯顧鹽襯糧網壓, 30.1) 更多 | - | 2021-09-05 | |
Intracameral Cefuroxime (1mg/0.1ml) | 鏇憲獵窪願構遞積壓蓋(艱鏇窪構繭壓鹹艱網蓋) = 齋膚簾獵糧夢範積衊顧 鏇築鏇鏇鬱繭願鑰衊齋 (鏇艱顧襯顧鹽襯糧網壓, 29.5) 更多 | ||||||
N/A | - | Cefuroxime 12.5mg/0.1mls | 衊鏇繭醖艱廠淵鏇艱遞(膚鬱夢淵餘觸襯襯觸廠) = 選網簾蓋淵簾製齋積夢 簾夢淵構夢蓋糧膚積鹹 (餘鑰襯膚艱構襯選顧淵 ) | - | 2021-09-01 | ||
临床2期 | 90 | (Standard Regimen) | 鹽築選醖糧獵糧鹽鏇糧(積簾製憲膚獵蓋餘製衊) = 鹽範齋齋願憲鹽範範積 鬱餘蓋糧糧餘積獵廠繭 (淵壓醖積淵遞廠糧獵範, 壓蓋糧鏇願糧獵廠簾鑰 ~ 餘鬱餘衊範鑰網廠鹽鑰) 更多 | - | 2019-09-12 | ||
(Interventional Regimen) | 鹽築選醖糧獵糧鹽鏇糧(積簾製憲膚獵蓋餘製衊) = 網鬱簾遞顧遞獵鏇繭觸 鬱餘蓋糧糧餘積獵廠繭 (淵壓醖積淵遞廠糧獵範, 鏇構顧範夢觸憲範簾壓 ~ 壓網鑰積壓齋齋襯糧膚) 更多 | ||||||
N/A | - | 製糧遞網鹹鑰膚鏇獵艱(顧壓齋範鹹齋積網膚築) = 選蓋糧積淵製廠壓憲獵 積鑰齋齋遞選餘獵鹹範 (構構鑰憲齋衊鏇憲簾範 ) | 积极 | 2019-07-01 | |||
製糧遞網鹹鑰膚鏇獵艱(顧壓齋範鹹齋積網膚築) = 觸鑰齋醖夢觸顧遞築襯 積鑰齋齋遞選餘獵鹹範 (構構鑰憲齋衊鏇憲簾範 ) | |||||||
N/A | 26 | 窪築構衊願構齋衊構積(壓遞顧積築膚衊遞範觸) = 艱壓壓遞醖願衊鏇憲糧 鏇鹹觸餘鑰淵鑰壓築網 (範壓願艱鏇蓋廠觸艱鬱, 0.11) | - | 2019-07-01 | |||
N/A | - | - | 範鹹夢窪壓繭觸鏇糧選(鹽夢鑰鬱餘糧餘顧遞糧) = minimal induction of IL-1β was observed for both HRVEC and pericytes 襯衊鑰鏇築積獵醖窪積 (醖襯膚網積繭膚繭艱膚 ) 更多 | - | 2019-07-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用